|
Orthologous residues
|
|
UBC3B (human): S233‑p, UBC3B (mouse): S233‑p, UBC3B (rat): S233‑p
|
|
Characterization
|
|
Methods used to characterize site in vivo:
[32P] bio-synthetic labeling, mutation of modification site, western blotting
|
|
Relevant cell lines - cell types - tissues:
293 (epithelial), HeLa (cervical)
|
|
Cellular systems studied:
cell lines
|
|
Species studied:
human
|
|
Enzymes shown to modify site in vitro:
|
|
|
|
Upstream Regulation
|
|
Potential in vivo enzymes for site:
|
|
Type
|
Enzyme
|
Evidence
|
Notes
|
|
KINASE
|
CK2-A1 (human)
|
pharmacological inhibitor of upstream enzyme, transfection of wild-type enzyme
|
|
|
|
Treatments, proteins and their effect on site modification:
|
|
Treatments
|
Referenced Treatments
|
Manipulated Protein
|
Referenced Protein
|
Effect
|
Notes
|
|
TBB
|
|
|
|
decrease
|
|
|
|
Downstream Regulation
|
|
Effect of modification (function):
molecular association, regulation
|
|
Effect of modification (process):
transcription, altered
|
|
Modification regulates interactions with:
|
|
Interacting molecule
|
Interacting domains
|
Effect
|
Consequences (function)
|
Consequences (process)
|
Detection assays
|
|
BRD8 iso1 (human)
|
|
Induces
|
molecular association, regulation
|
|
pull-down assay, in vitro
|
|
|
Comments:
CK2-dependent phosphorylation of UCB3C leads to beta-catenin degredation and inhibition of beta-catenin transcription.
|
